Khloe Kardashian's Khloud dusts seven grams onto each bag, and Starbucks has put it next to the till. Doritos Protein arrives this year with ten grams a serving. Pop-Tarts went protein last November. There is protein water. There is protein coffee, and proffee sales rose 507% in a single year while traditional protein shakes fell 40%. Bloomberg ran the headline the industry had been avoiding: welcome to peak protein.

When a nutrient ends up in everything, the interesting question is not why it is winning. It is why it has to keep shouting.

This is a deep dive into what happens next. Why the protein wave is real but finished as a source of margin, why it will keep growing anyway, and why fibre is the genuine white space underneath it. Then the part that matters if you are actually building: who has raised, who has share, and the single reason most fibre brands will fail even though the demand is real.

Start with the absurdity, because the absurdity is the signal.

Protein has stopped being a claim and become a reflex. Ramen, ice cream, pizza, soda, pancakes, cereal, candy. Sweetgreen ran an entire campaign last year mocking protein popcorn and protein cold foam. Seventy percent of US adults now actively try to consume protein, more than any other nutrient.

You do not put a nutrient in water because there is unmet demand for it. You put it there because the obvious formats are saturated and the only growth left is to colonise formats that never needed it.

That is the tell. When a category is healthy, brands compete on being better. When a category is saturated, brands compete on being everywhere. Protein has moved from the second phase to the third.

The numbers confirm it. Consumer interest in protein snacks has flattened to +0.9% year on year, with researchers describing consumers as oversaturated. Protein snacks are now judged like any other snack, on taste and texture, because the nutrition claim no longer differentiates anything.

Here is where it stops being funny.

The protein boom has broken its own supply chain. Whey is a byproduct of cheesemaking, which means you cannot simply make more of it without making more cheese. Demand has outstripped supply so badly that high-protein whey concentrate jumped 40% in a matter of months and some suppliers have sold out for the entire year.

The consequence is brutal and instructive. Smaller brands are reformulating to worse products. One founder described her reformulated pancake mix as "complete sawdust." Another had to ditch inventory altogether. When a category forces its own participants to make their products worse to stay on shelf, that category is no longer a place to build margin. It is a place to defend it.

At the Consumer Analyst Group of New York conference this year, Kerry Group described protein not as a benefit but as a "design requirement". Read that carefully. A design requirement is not something you win with. It is something you are penalised for lacking. Protein has become table stakes, and table stakes do not command a premium.

This is the definition of a red ocean. High demand, brutal competition, collapsing differentiation, rising input costs, thinning margins. Everyone is in the water and the water is full of blood.

Now the nuance that separates this analysis from every lazy "peak protein" take you will read this quarter.

Protein is going to keep growing. It is not a fad unwinding. Two structural forces guarantee it.

First, the US dietary guidelines were revised upward, lifting recommended protein from 0.8g per kilo of bodyweight to between 1.2 and 1.6g, with three daily servings of full-fat protein. That is a permanent baseline shift, not a trend.

Second, and more important, GLP-1. The weight-loss drugs suppress appetite so aggressively that users lose muscle alongside fat. To defend that muscle, they have to pivot to nutrient-dense, protein-heavy food in smaller portions. Around 10% of the US population has now taken a GLP-1 drug. Every one of them is a structural, medically-driven protein customer for as long as they are on the medication.

So protein grows. But it grows as infrastructure, not as opportunity. It grows the way electricity demand grows, reliably and without margin, because everyone already supplies it and nobody can charge a premium for it.

The clearest signal comes from inside the protein industry itself. Todd Spear, VP at Protein Research, put it on record: he does not believe fibre will supplant protein, but he expects protein to decline somewhat while developers and consumers pivot to fibre, "a nutrient the vast majority of Americans don't consume enough of."

When a protein insider tells you the smart money is rotating to fibre, the rotation has already started.

White space is rare, and it is almost never empty because everyone missed it. It is empty because it was hard. Fibre is both.

Four things make it the genuine frontier.

The deficiency is near-universal. Around 95% of adults in the UK and US fail to hit recommended fibre intake. UK guidance is 30g a day. Average intake sits around 20g. Protein's story was aspirational, sold to people who already believed they were healthy. Fibre's story is remedial, and remedial has a structural advantage: you never graduate from a deficiency. Protein has a finish line. Fibre does not.

Gut diversity became mainstream health literacy. A decade of microbiome research taught consumers that the variety of bacteria in the gut governs digestion, immunity, mood and metabolism, and that fibre is what feeds that variety. More than 80% of consumers in the UK, US and China now consider gut health important, and over half say it will become a higher priority. That is demand education the fibre category did not have to pay for.

Probiotics and prebiotics already primed the pump. The gut category has had a commercial decade. Kefir, kombucha, yoghurt shots, probiotic pills. The UK probiotics market alone is worth around $2bn. But probiotics add bacteria, while fibre feeds the bacteria you already have. Fibre is the logical next chapter of a story consumers have already been reading for years. The audience is warm. The shelf is not yet crowded.

GLP-1 needs fibre specifically. The same drug wave saturating protein opens fibre, because appetite suppression creates demand for satiety, digestive tolerability and nutrient density in smaller portions. Fibre is the only macronutrient that delivers fullness at near-zero calories. It also manages the constipation and digestive discomfort that plague GLP-1 users. Protein defends the muscle. Fibre manages the appetite and the side effects. Same customer, same drug, same moment.

And the demand is already showing up as money, not just curiosity. The Vitamin Shoppe, drawing on till data from over 640 stores, reported fibre category sales up 20% year to date, site searches for "fiber" up 59%, and searches for "psyllium husk" up 150%. It named fibre the number one of five defining wellness trends for 2026. That is retail spend, not Google Trends. Far harder evidence.

One more thing fibre has that protein never will. Research in the British Medical Journal found every additional 10g of daily fibre cuts bowel cancer risk by around 10%. No protein brand has a claim in that weight class. This is not a wellness category. It is a public health category wearing a wellness category's clothes.

The capital has noticed. Here is the field as it stands in mid-2026, and the strategic split running straight down the middle of it.

Myota. Raised $4.5m Series A in June 2026, led by PeakBridge. Founded 2022 by microbiome scientist Dr Thomas Gurry and Kat Stennett. UK DTC tripled to over 60,000 customers on the back of seven clinical trials and patented multi-fibre blends engineered to maximise short-chain fatty acid production while minimising the gastrointestinal discomfort that comes with high fibre intake.

The critical detail almost everyone misses: Myota did not raise to build a supplement brand. They raised to build an ingredient platform. The capital funds a B2B sales operation selling patented blends into dairy, bakery and functional beverage, with a global partnership already signed with Joe & The Juice. DTC is the proof asset. B2B is the business. Picks and shovels in a gold rush.

Bio&Me. Around $7.6m raised in total, first round £1.4m closed in 72 hours in 2022, backers including Harry Kane. Founded 2019 by Dr Megan Rossi, a King's College London research fellow with over 50 peer-reviewed papers, alongside operator Jon Walsh. This is the biggest fibre-native business in the UK by revenue: a £22m quarterly run-rate, 52% growth year on year, profitable for the first time last year, the number one kefir SKU in Sainsbury's, ranked 60th in the Sunday Times 100, now in Costco and expanding into Sweden, Iceland and France.

Bio&Me did not sell fibre. It sold granola, porridge, muesli, kefir and bars, with fibre inside the format people already eat. Walsh gave up the number that matters in an interview: the magic repeat rate is 40%, Bio&Me has now passed it on its key lines, and the majority of growth now comes from increased rate of sale rather than new distribution. Distribution is borrowed growth. Rate of sale is earned growth.

ZOE. $118m raised, backers including Balderton and Coefficient. Founded 2017 by Prof Tim Spector. Over 100,000 subscribers, revenue estimated above $100m, more than 70% recurring. Not a fibre brand, a subscription health platform that sells fibre. Daily30+ carries over 30 plants and 35 types of fibre. ZOE built the demand infrastructure first, through Spector's podcast, books and the PREDICT study, and monetised it second. That sequence is the most expensive asset in consumer, and they built it before they needed it.

LOAM Science. Founder-funded, launched 2025 by NHS surgeon Dr Karan Rajan, who has over 10 million followers. He spent close to $20,000 buying competitor fibre supplements before formulating, and concluded the problem was not science but experience: most products were viscous, unpleasant, single-fibre at low dose. LOAM is six soluble prebiotics, tasteless, odourless, fully dissolving. He built it publicly, taking ten million people through development. Near-zero acquisition cost on day one. The fastest route to revenue in the category and the hardest to defend, because the moat is a person.

The rest of the UK field is filling fast: The Gut Stuff (bars, drinks, a 30g fibre challenge, listed in Sainsbury's, Tesco, Co-op), Deeply (fibre shots, sales more than doubled), Gut Wealth (£300k raised), Nolo (fibre inside cold brew coffee) and Unrooted (baobab sachets on Ocado, where fibre searches rose 57% year on year).

Supergut. $36m to $41m raised, Series B led by Full Frame Growth Partners. Founded 2019 by Marc Washington, a career CPG operator (ex-Beachbody COO, ex-Irwin Naturals CEO). Revenue up 172% in 2024, sales tripled year on year, now nationwide in Walmart alongside Target, GNC, Sprouts and Erewhon.

Watch what happened when growth equity arrived. Washington moved to executive chairman and Tracey Warner Halama, former CEO of Vital Proteins, took over as CEO with a plan that was not about science at all: double the door count, fortify omnichannel. Washington has since left to become President and CFO of iFIT. The founder built the credibility. The operator monetised it.

OLIPOP and poppi. OLIPOP raised a $50m Series C at a $1.85bn valuation on over $400m revenue. poppi was acquired by PepsiCo for $1.95bn. Neither is a fibre brand in the Myota sense. Both are sodas that used prebiotic fibre as permission to sell soda to people who had quit soda. They are also the two biggest financial outcomes in the entire category.

Pendulum. Live bacterial strains plus fibre, peer-reviewed trials, Halle Berry attached as investor and advocate. Glucose Control validated in a double-blind trial showing a 0.6-point A1C reduction.

Acquisition is the easy half. These operators run the hard part on TikTok Shop.

The partners I work with run TikTok Shop for brands you already know. Grüns, Goli and Vita Coco in the US. Pukka, Proper and ManiLife in the UK. Both are official TikTok Shop agency partners, one per market, and I only make introductions I would make for myself. Tell me where you are in two minutes and I will match you to the right one.

Get matched to a TikTok Shop partner →

Line up the UK founders. Gurry: PhD, microbiome. Rossi: PhD, King's College research fellow. Spector: professor, one of the world's most-cited scientists. Rajan: NHS surgeon. Four doctors.

Now line up the outcomes. OLIPOP: $1.85bn. poppi: $1.95bn. Supergut: 172% growth, national Walmart. Every one run by CPG operators, not scientists.

The UK has the science. America has the scale.

This is not a talent gap. It is a sequencing gap. British fibre brands lead with evidence and hope distribution follows. American fibre brands lead with distribution and buy the evidence later. The two UK exceptions prove it: Bio&Me and Supergut are the best-performing businesses in their markets, and both paired a scientist with an operator who had already scaled a P&L. Science is a moat. A moat is worthless without a castle inside it.

Here is the thing nobody in the category says out loud.

Read the founder interviews as a churn analysis instead of a product spec. Rajan's $20,000 finding: viscous, unpleasant, single-fibre. Myota's core technical claim: minimising the gastrointestinal discomfort of high fibre. Every credible source warns that increasing fibre too fast from a low baseline causes bloating, cramps and constipation.

Now translate. Viscous is a reason to skip a day. Unpleasant taste is a reason to skip a week. Bloating in week one is the single largest quit trigger in the category, and it lands precisely when the customer has paid but not yet felt any benefit.

Nobody in fibre is losing on efficacy. They are losing on week two.

The benefit is invisible and delayed. The cost is immediate and physical. That is the worst retention curve shape in consumer subscription, and it is the real reason this white space stayed empty for decades. Metamucil owned fibre and it was never cool, because the experience was genuinely worse than the alternatives. The frontier was not unclaimed because nobody noticed. It was unclaimed because it is hard.

Every serious operator has independently arrived at the same answer without naming it: fix the experience, not the formula. LOAM's product thesis is a retention thesis in a formulation costume. Myota's patent is a retention patent. Bio&Me's 40% repeat rate is a format achievement: they put fibre inside granola so nobody has to remember to take it.

Fibre is a Month 2 retention category. Everything else is noise.

One last turn, because "fibre is the next protein" is already becoming the consensus take, and consensus is not an edge.

The deepest white space is not fibre as the next single hero nutrient. It is the end of the single hero nutrient altogether.

Protein won by being a mono-claim. One number on the front of pack. But look at what the GLP-1 customer actually needs: protein to defend muscle and fibre to manage appetite and digestion, at the same time, in the same smaller portion. The winning formats already pair them. Nestlé's GLP-1 shake is protein plus prebiotic fibre. GlobalData's analyst describes the emerging demand as "high-protein, high fibre, nutrient-dense, portion-controlled" in a single breath.

The brands betting on fibre as the new mono-hero are fighting the last war. The real frontier is the combination, and the reason it is still open is that pairing claims and solving adherence at the same time is a formulation and retention problem most brands cannot execute.

That is the whole game. Not picking the next nutrient. Building the system that gets a customer past week two and into month three, whatever is written on the front of the pack.

Protein is not the loser here and fibre is not automatically the winner.

The winner is whoever gets the customer to Month 3.

Build the onboarding as a titration protocol, not a benefits explainer. The category over-educates on why fibre matters and under-prepares the customer for week one. Start them low. Tell them the bloating is coming and that it resolves in one to two weeks. Give them a water target. Every operator who has solved retention here solved it at this exact point, and none of them talk about it.

Pick your play and commit. Credibility, audience, format or ingredient. Myota picked ingredient and raised on it. LOAM picked audience and needed no capital. Bio&Me picked format and reached £22m a quarter. The brands that fail will be the ones trying to be a clinically-validated, creator-led, retail-listed ingredient supplier all at once. Pepsi is on this shelf now. Ambiguity is fatal.

If you are science-led, hire the operator before you need them. The two best fibre businesses in their markets both paired a scientist with someone who had scaled a P&L. If you have a PhD, a trial and no distribution, your next hire is not another scientist. Your defensibility is already built. Your problem is that nobody can buy it.

Forward this to a founder about to launch into fibre, or one already in it and quietly watching their repeat rate flatten.

If your subscription business acquires well and retains badly, that is a diagnosable problem with a fixable cause.

Apply here → apply.consciouscommerceco.com/diagnose